Case Studies of RWE Submissions Leveraging CDISC Compliant RWD Real-World Evidence (RWE) is increasingly becoming an essential component in regulatory submissions within the pharmaceutical and medical technology industries. As organizations strive to align their data with regulatory expectations, understanding the integration of CDISC (Clinical Data Interchange Standards Consortium) frameworks like SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) into real-world data (RWD) submissions is critical. This article provides a comprehensive step-by-step tutorial on leveraging CDISC-compliant RWD, focusing on practical case studies, regulatory guidelines, and integration of data standards. Understanding Real-World Evidence and Its Regulatory Relevance RWE is defined…

Building RWE Data Pipelines that Respect CDISC and FDA Data Standards Building RWE Data Pipelines that Respect CDISC and FDA Data Standards Real-World Evidence (RWE) has increasingly become a cornerstone of modern healthcare decision-making, providing insights beyond traditional clinical trial data. With a growing emphasis on data standards such as CDISC (Clinical Data Interchange Standards Consortium), the importance of developing RWE data pipelines compliant with FDA regulations cannot be overstated. In this comprehensive tutorial, we will guide you step by step through building RWE data pipelines that adhere to CDISC and FDA data standards, focusing on the integration of various…

HL7 FHIR as a Bridge Between EHR Data and RWE Analytic Datasets HL7 FHIR as a Bridge Between EHR Data and RWE Analytic Datasets The integration of clinical data into real-world evidence (RWE) analytics is a critical component of driving innovation and regulatory compliance in the pharmaceutical and medtech industries. A prominent framework that helps in achieving this integration is Health Level 7 Fast Healthcare Interoperability Resources (HL7 FHIR). This tutorial will provide a comprehensive step-by-step guide to understanding how HL7 FHIR acts as a bridge between Electronic Health Record (EHR) data and RWE analytic datasets, focusing on critical aspects…

Converting Messy RWD into CDISC SDTM and ADaM Formats for Regulators Real-world data (RWD) has become increasingly significant in determining healthcare outcomes, drug efficacy, and safety. As regulatory bodies like the U.S. Food and Drug Administration (FDA) continue to evolve their initiatives, a standardized approach to data representation becomes essential in ensuring compliance and facilitating regulatory review. One core component of this initiative involves structuring RWD into Clinical Data Interchange Standards Consortium (CDISC) formats, namely the Study Data Tabulation Model (SDTM) and the Analysis Data Model (ADaM). This tutorial serves as a comprehensive guide for professionals in pharma and medtech…

Regulatory Expectations for Traceability from Source RWD to Analysis Data Introduction to Real-World Evidence (RWE) and Data Standards The integration of Real-World Evidence (RWE) into drug development and post-marketing surveillance has gained significant momentum, particularly due to its potential to complement traditional randomized controlled trials (RCTs). Regulatory bodies, including the U.S. Food and Drug Administration (FDA), emphasize the necessity of robust data standards in ensuring the integrity of analyses derived from RWE. This article serves as a comprehensive tutorial on the regulatory expectations regarding traceability from source RWD to analysis data, highlighting frameworks such as the Clinical Data Interchange Standards…

Designing Common Data Models that Support RWE Across Indications Designing Common Data Models that Support RWE Across Indications In the rapidly evolving landscape of healthcare data, designing common data models that support real-world evidence (RWE) across indications is critical for effective regulatory submissions and health outcomes research. This tutorial provides a step-by-step guide for regulatory, biostatistics, HEOR, and data standards professionals in pharma and medtech to navigate the complexities of data standards such as CDISC, SDTM, ADaM, and HL7/FHIR. Establishing a clear framework is essential for ensuring compliance and optimizing the utilization of RWE in regulatory settings. Understanding the Importance…

Quality Checks and Validation Rules for SDTM and ADaM RWE Datasets In the evolving landscape of clinical research, Real-World Evidence (RWE) plays an increasingly pivotal role in informing healthcare decisions. Data standards such as CDISC, SDTM, ADaM, and HL7/FHIR are essential for ensuring the integrity, consistency, and usability of RWE datasets. This article offers a comprehensive tutorial on the quality checks and validation rules necessary to meet regulatory expectations for these datasets, particularly for audiences in the US but also considering UK and EU standards. Understanding the Regulatory Framework for RWE Datasets The US Food and Drug Administration (FDA) has…

Working with CROs and vendors on CDISC and FHIR implementation for RWE Working with CROs and Vendors on CDISC and FHIR Implementation for RWE In the evolving landscape of regulatory submissions and real-world evidence (RWE), collaboration with Contract Research Organizations (CROs) and various data vendors is crucial. As regulations and expectations set forth by the FDA and other global regulatory agencies become more demanding, understanding the intricacies of data standards RWE CDISC SDTM ADaM HL7 FHIR is fundamental for successful compliance and implementation. This article will provide a step-by-step tutorial on effectively working with CROs and vendors to ensure adherence…

Metadata and Controlled Terminology Strategies for RWE Data Standards The increasing importance of real-world evidence (RWE) in drug development and market access has created a pressing need for robust data standards. As professionals in pharma and medtech navigate this complex landscape, understanding metadata and controlled terminology strategies is critical. This comprehensive tutorial examines the foundational elements of RWE data standards, focusing on key frameworks such as CDISC, SDTM, ADaM, and HL7/FHIR. Understanding Real-World Evidence (RWE) and Data Standards Real-world evidence refers to the clinical evidence derived from data collected outside of conventional clinical trials. This includes data from electronic health…

Future Convergence of FHIR, OMOP, and CDISC in the RWE Ecosystem In recent years, the emergence of real-world evidence (RWE) has transformed how pharmaceutical and biotechnology companies approach clinical trials, regulatory submissions, and post-market surveillance. Understanding the integration of various data standards, particularly FHIR (Fast Healthcare Interoperability Resources), OMOP (Observational Medical Outcomes Partnership), and CDISC (Clinical Data Interchange Standards Consortium) is crucial for regulatory, biostatistics, HEOR, RWE, and data standards professionals. In this tutorial, we will outline a step-by-step approach to navigate the confluence of these data standards in the RWE ecosystem. Understanding the Role of CDISC in RWE CDISC…